Otsuka says kidney disease drug preserves function in late-stage study

• The study of 320 participants showed Voyxact increased estimated glomerular filtration rate (eGFR) while placebo patients saw decline, with 24-month data expected in two months
• Voyxact is a monoclonal antibody administered every four weeks that can be given by caregivers or self-administered at home for patient convenience
• Otsuka has begun rolling submission to the FDA for traditional approval based on 24-month trial data, competing with Vera Therapeutics and Vertex Pharmaceuticals in the IgAN treatment space

Otsuka Pharmaceutical Kidney Disease Drug Shows Promise in Late-Stage Trial

Otsuka Pharmaceutical announced on June 4 that its investigational drug Voyxact (sibeprenlimab) successfully preserved kidney function in a late-stage clinical trial for patients with primary immunoglobulin A (IgA) nephropathy, an autoimmune disease causing kidney inflammation.

Key Trial Results:

The 12-month study involving 320 participants demonstrated that patients receiving Voyxact showed increased kidney function as measured by estimated glomerular filtration rate (eGFR), while placebo patients experienced functional decline. The drug also reduced proteinuria, with Chief Medical Officer John Kraus noting that proteinuria reduction translated to preserved kidney function—described as "incredibly encouraging."

Disease Background:

IgA nephropathy occurs when immunoglobulin A antibodies accumulate in kidneys, causing inflammation, tissue damage, and protein/blood leakage into urine, potentially leading to kidney failure.

Product Details:

Voyxact is a monoclonal antibody administered every four weeks, offering convenient at-home administration options through caregivers or self-injection.

Regulatory Timeline:

Otsuka expects 24-month data from the same trial within two months and has initiated a rolling submission to the U.S. FDA seeking traditional approval based on this longer-term data.

Competitive Landscape:

Other companies developing IgAN treatments include Vera Therapeutics and Vertex Pharmaceuticals, indicating growing industry focus on this condition.

Market Implications:

The positive trial results position Otsuka competitively in the emerging IgAN treatment market. Successful FDA approval could address significant unmet medical needs for patients with this progressive kidney disease, representing a substantial commercial opportunity in the nephrology therapeutic space.